Year End results as of December 31,2024
|
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Annual Results Vitruvia Medical AG: Year End results as of December 31, 2024
Anglikon, May 3, 2025: Vitruvia Medical AG achieved a result after taxes of CHF -173’775.93 in the past year 2024 compared to CHF -243’896.10 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 2’108’483.00 (previous year EUR 1,757,724.00 / +20%) and earnings before interest, taxes, depreciation and amortization (EBITA) of EUR 178’398.00, compared with EUR 61,078.00 in the previous year (+192%). Earnings after taxes and amortization of goodwill amounted to EUR -384’086.00 compared with EUR-535,435.00 in the previous year LT technologies has achieved its sales and profit expectations for 2024. For 2025, we expect LT technologies' activity to continue to pick up, which will be reflected in the sales and profit figures.
About Vitruvia Medical AG: Vitruvia Medical AG is a Swiss investment company focusing on the repair, production and trade of medical devices as well as surgical instruments. Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.
End of Inside Information
03-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vitruvia Medical AG |
| Kesselackerstr. 18 | |
| 5611 Anglikon | |
| Switzerland | |
| Phone: | +41 44 915 33 78 |
| E-mail: | kontakt@vitruvia-med.com |
| Internet: | www.vitruvia-med.com |
| ISIN: | CH0461931419 |
| WKN: | A2PDWF |
| Listed: | Regulated Unofficial Market in Munich |
| EQS News ID: | 2129406 |
| End of Announcement | EQS News Service |
|
|
2129406 03-May-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.